Correction (DOI:10.1016/j.amjcard.2005.11.039);Effects of Colesevelam Hydrochloride on Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein When Added to Statins in Patients With Hypercholesterolemia

American Journal of Cardiology

Volumn 97, Issue 8, 2006, Pages 1198-1205

  Bays, Harold E ^a   Davidson, Michael ^b,c   Jones, Michael R ^d   Abby, Stacey L ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b RADIANT RESEARCH   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; COLESEVELAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; ANALYTIC METHOD; ARTICLE; CHOLECYSTITIS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TRANSIENT ISCHEMIC ATTACK;

EID: 33645735636     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.05.010     Document Type: Erratum

References (30)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. The Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984) 351-364
3. The Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 (1984) 365-374
4. Brensike J.F., Levy R.I., Kelsey S.F., Passamani E.R., Richardson J.M., Loh I.K., Stone N.J., Aldrich R.F., Battaglini J.W., Moriarty D.J., et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis. results of the NHLBI Type II Coronary Intervention Study. Circulation 69 (1984) 313-324
5. Levy R.I., Brensike J.F., Epstein S.E., Kelsey S.F., Passamani E.R., Richardson J.M., Loh I.K., Stone N.J., Aldrich R.F., Battaglini J.W., et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease. results of NHLBI Type II Coronary Intervention Study. Circulation 69 (1984) 325-337
6. Watts G.F., Lewis B., Brunt J.N., Lewis E.S., Coltart D.J., Smith L.D., Mann J.I., and Swan A.V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 (1992) 563-569
7. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., and Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 (1987) 3233-3240
8. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., and Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
9. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., and Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264 (1990) 3007-3012
10. Whitney E.J., Krasuski R.A., Personius B.E., Michalek J.E., Maranian A.M., Kolasa M.W., Monick E., Brown B.G., and Gotto Jr. A.M. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels. effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
11. Bays H., and Dujovne C. Colesevelam HCl. a non-systemic lipid-altering drug. Expert Opin Pharmacother 4 (2003) 779-790
12. Davidson M.H., Toth P., Weiss S., McKenney J., Hunninghake D., Isaacsohn J., Donovan J.M., and Burke S.K. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 24 (2001) 467-474
13. Hunninghake D., Insull Jr. W., Toth P., Davidson D., Donovan J.M., and Burke S.K. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158 (2001) 407-416
14. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., Donovan J.M., Burke S.K., and Davidson M.H. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110 (2001) 352-360
15. Frolkis J.P., Pearce G.L., and Sprecher D.L. Impact of nonprescriptive factors on low-density lipoprotein cholesterol reduction with statins. Am J Cardiol 94 (2004) 1310-1312
16. Ferramosca E., Burke S., Chasan-Taber S., Ratti C., Chertow G.M., and Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149 (2005) 820-825
17. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., Ganda O.P., Rosenson R.S., Buse J.B., Robertson D.D., and Sheehan J.P. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 162 (2002) 1568-1576
18. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D., Bays H.E., and Simmons P.D. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89 (2002) 672-678
19. Sager P.T., Capece R., Lipka L., Strony J., Yang B., Suresh R., Mitchel Y., and Veltri E. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179 (2005) 361-367
20. Bays H.E., Ose L., Fraser N., Tribble D.L., Quinto K., Reyes R., Johnson-Levonas A.O., Sapre A., and Donahue S.R. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
21. Ridker P.M. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 26 (2003) III39-III44
22. Liepa G.U., and Basu H. C-reactive proteins and chronic disease. what role does nutrition play?. Nutr Clin Pract 18 (2003) 227-233
23. Moriarity P., Gibson C., Shih J., and Matias M. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158 (2001) 495-498
24. Rizos E., Kostoula A., Elisaf M., and Mikhailidis D.P. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 53 (2002) 273-277
25. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., and Stegnar M. Statin and fibrate treatment of combined hyperlipidemia. the effects on some novel risk factors. Thromb Haemost 92 (2004) 1129-1135
26. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
27. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., and Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia. relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
28. De-Maat M., Knipscheer H., Kastelein J., and Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost 77 (1997) 75-79
29. Ikonomidis I., Andreotti F., Economou E., Stefanadis C., Toutouzas P., and Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100 (1999) 793-798
30. Woodward M., Lowe G.D., Francis L.M., Rumley A., and Cobbe S.M. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction. the CADET trial. J Thromb Haemost 2 (2004) 1934-1940